14th Nov 2008 07:00
Embargoed Release: 07:00hrs Friday 14 November 2008
Plethora Solutions Holdings plc
Holdings in the Company
Plethora Solutions Holdings PLC ("Plethora", AIM : PLE), the specialist developer of products for the treatment and management of urological disorders, has been notified that Merlin Biosciences Fund III GmbH & Co KG has transferred its interest in 1,525,250 ordinary shares of £0.10 each in the capital of the Company, representing approximately 5.4% of the issued share capital of the Company, to Merlin Biosciences Fund III 2007 L.P.
-Ends-
Enquiries:
|
Plethora Solutions Steven Powell |
Tel : +44(0) 20 3077 5400 |
|
FinnCap Geoff Nash |
Tel: +44(0) 20 7600 1658 |
|
Hansard Group Adam Reynolds/John Bick |
Tel: +44(0) 20 7245 1100 |
About Plethora:
Plethora is focused on the development and marketing of products for the treatment of urological disorders. The Company has products in clinical development for the treatment of overactive bladder, stress urinary incontinence, interstitial cystitis, gynaecological pain, erectile dysfunction and premature ejaculation. In January 2006, Plethora acquired Minneapolis (Mn) based Timm Medical Technologies Inc., which markets products for the treatment of erectile dysfunction (ED) to urology clinics through a US-based specialty sales team. The Company is headquartered in the UK and is listed on the London Stock Exchange (AIM:PLE)
Further information is available at www.plethorasolutions.co.uk
Related Shares:
Plethora Solutions Holdings Plc